We’re thrilled to announce our first strategic collaboration with @Sanofi to develop a next-generation RNA therapeutic designed to eliminate expression of the DUX4 gene responsible for causing the disease in 95% of FSHD patients. Read more here: mirecule.com #biotech
miRecule, Inc.
@mireculeinc
miRecule™ is a biotechnology company dedicated to realizing the potential of tissue-targeted RNA therapies for cancer and muscular dystrophy.
9 Following 21 Followers 1 Posts